Une publication dopée par le dollar, guidances relevées - NEUTRE - OC 67€
Le groupe publie ce matin son CA du 9m qui se révèle globalement en ligne avec les attentes. Grâce à un effet de change favorable et une diminution des coûts de commercialisation, UCB ajuste à la hausse ses estimations sur l'année, à savoir des revenus initialement compris entre 3,65 et 3,75Mds€, sont attendus aujourd'hui en haut de fourchette autour de 3,75Mds€, un EBITDA qui était attendu entre 710 et 740m€ est aujourd'hui espéré proche des 800m€ et un Core EPS qui passe d'une fourchette comprise entre 1,90€-2,05€ à 2,0€-2,10€. Nous maintenons à ce stade notre recommandation à NEUTRE avec un objectif de 67€.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.